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Abstract
Background: Cerebrospinal fluid (CSF) pleocytosis may be seen in asymptomatic HIV-infected
individuals. This finding complicates interpretation of CSF abnormalities when such individuals are
evaluated for other central nervous system infections. The goal of this study was to determine the
relationship between CSF pleocytosis, central nervous system (CNS) antiretroviral penetration,
adherence to antiretroviral medication regimens, neurological symptoms and performance on
neuropsychological tests.
Methods: Clinically stable HIV-infected individuals at any peripheral blood CD4+ T cell count or
any plasma viral load were asked to attend study visits at entry and every 6 months thereafter for
at least one year. At each visit, they underwent a standardized neurological and medication history;
neurological examination; a brief neuropsychological test battery: venipuncture; lumbar puncture;
and assessment of medication adherence. Generalized estimating equations (GEE) were used to
assess the relationships between CSF pleocytosis and other variables.
Results: CSF pleocytosis was independently and significantly related to lack of current
antiretroviral use (OR 5.9, 95% CI 1.8–18.6, p = 0.003), CD4 count > 200/ul (OR 23.4, 95% CI 3.1–
177.3, p = 0.002) and detectable plasma HIV RNA (OR 3.3, 95% CI 1.1–9.4, p = 0.03). At visits
where antiretrovirals were used, and taking into account detectable plasma HIV RNA, an
antiretroviral regimen that contained two or more agents with good CNS penetration conferred
a trend toward lower odds of CSF pleocytosis (OR 0.45, 95% CI 0.18–1.12, p = 0.087).
Conclusion: CSF pleocytosis is a characteristic of HIV disease that varies significantly with easily
identifiable clinical and laboratory features. Use of antiretroviral agents decreases the odds of
pleocytosis. This association may be stronger when the regimen contains two or more agents with
good CNS penetration.
Published: 2 May 2007
BMC Infectious Diseases 2007, 7:37 doi:10.1186/1471-2334-7-37
Received: 5 February 2007
Accepted: 2 May 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/37
© 2007 Marra et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
BMC Infectious Diseases 2007, 7:37 http://www.biomedcentral.com/1471-2334/7/37Background
Cerebrospinal fluid (CSF) pleocytosis is common in HIV-
infected individuals who do not have other central nerv-
ous system infections (CNS), and it is not accompanied
by neurological symptoms or abnormalities on neuropsy-
chological tests [1-4]. Several studies show that CSF HIV
RNA concentration increases with increasing CSF white
blood cells (WBC) [4-6]. CSF pleocytosis decreases after
antiretroviral treatment, even when the regimen is only
partially effective, and treatment interruption may lead to
increases in CSF WBC [1,7]. Most studies have focused on
correlates of CSF viral replication, rather than on CSF ple-
ocytosis. A better understanding of the factors that influ-
ence HIV-related CSF pleocytosis would assist in
interpretation of CSF abnormalities when CNS infection
other than HIV is suspected. The goal of this study was to
determine the relationship between CSF pleocytosis, CNS
antiretroviral penetration, adherence to antiretroviral
medication regimens and performance on neuropsycho-
logical tests. Our results show that CSF pleocytosis is a
characteristic of HIV disease that varies significantly with
easily identifiable clinical and laboratory features.
Methods
After written consent was obtained, clinically stable HIV-
infected individuals with any peripheral blood CD4 count
or any plasma viral load were asked to attend study visits
at entry and every 6 months thereafter for at least one year.
At each visit, they underwent a standardized neurological
and medication history; neurological examination; brief
neuropsychological test battery that included timed gait,
grooved pegboard with the dominant hand, finger tap-
ping with the nondominant hand and digit symbol;
assessment of antiretroviral drug adherence [8]; venipunc-
ture; and lumbar puncture. Adherence was defined as tak-
ing ≥ 95% of prescribed doses in the 4 days before each
visit on a standardized self-reported questionnaire. Based
on review of medical records, and on medical history and
physical examination, no subject had an intercurrent ill-
ness other than HIV. No subject underwent lumbar punc-
ture for clinical indications. The study protocol was
reviewed and approved by the University of Washington
Institutional Review Board. Human experimentation
guidelines of the University of Washington were followed
in the conduct of this research.
Cerebrospinal fluid WBCs and HIV RNA were considered
as dichotomous variables: CSF pleocytosis was defined as
CSF WBC > 5/ul and plasma and CSF samples with HIV
RNA ≤ 50 copies/ml were considered undetectable. This
approach was justified for two related reasons. First, these
variables show dichotomous distributions (normal or
undetectable vs. elevated or detectable) mixed with
skewed continuous distributions for values above the lim-
its of normal or detectable. This precludes the use of any
simple regression model. Second, the presence or absence
of pleocytosis or detectability of HIV RNA are more clini-
cally relevant to our analysis than the magnitude of the
abnormal values. As in other studies, we defined drugs
with good CNS antiretroviral penetration as zidovudine,
abacavir, stavudine, nevirapine, efavirenz, lamivudine
and indinavir [9]. We categorized regimens containing
none or one of these agents as poorly penetrant regimens
and those containing two or more of these agents as pen-
etrant regimens. Z scores were calculated for each neu-
ropsychological test using age-adjusted norms [10], and a
composite Z score (NPZ4) was calculated at each visit.
Values greater than 3 standard deviations above or below
the mean were considered outliers (two scores of less than
-3.0 standard deviations from two different subjects) and
were excluded. Baseline associations were determined
using Fisher's exact or chi-square tests. Generalized esti-
mating equations (GEE) were used to assess the relation-
ship between variables of interest over all study visits,
which allowed us to include data from subjects who
changed their antiretroviral regimen, account for correla-
tion between same-subject visits, examine potential time
trends and control for these if necessary. All tests were
two-tailed and p values ≤ 0.05 were considered signifi-
cant.
Results
Fifty subjects were enrolled and underwent a total of 143
visits (median 3, range 1–6). Median study participation
was 11.9 months (range 0–30). Subject characteristics at
entry are shown in Table 1; their demographic character-
istics are representative of our hospital's HIV clinic attend-
ees during the same time period (personal
communication, Mari Kitahata, MD, 02/23/2006). Of the
33 subjects taking antiretrovirals at entry, the median
number of agents was 3 (range, 2–5). During the study, 18
of 33 subjects made changes in their antiviral regimen.
Four subjects who entered the study on antiretrovirals
were not taking them at one study visit, and two subjects
initiated treatment. One subject who stopped antiretrovi-
rals and then started them again had an increase in CSF
WBCs from 7/ul to 218/ul, suggesting an immune recon-
stitution syndrome. No subject had intercurrent CNS
infection apart from HIV.
At entry, CSF pleocytosis was significantly more likely in
subjects not taking antiretrovirals (p = 0.001); and with
peripheral blood CD4+ T cells > 200/ul (p = 0.04), detect-
able plasma HIV RNA (p = 0.05) and detectable CSF HIV
RNA (p = 0.001). In a multivariate model including all
visits, CSF pleocytosis remained independently and sig-
nificantly related to lack of current antiretroviral use,
peripheral blood CD4+ T cells > 200/ul and detectable
plasma HIV RNA, but not to detectable CSF HIV RNA
(Table 2). There was no relationship between CSF pleocy-Page 2 of 5
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its where antiretrovirals were used, and taking into
account detectable plasma HIV RNA, an antiretroviral reg-
imen that contained two or more agents with good CNS
penetration conferred a trend toward lower odds of CSF
pleocytosis (OR 0.45, 95% CI 0.18–1.12, p = 0.087).
There were no significant time trends.
The most common neurological symptoms at entry were
mild or moderate difficulty concentrating in 15 (30%)
subjects and mild or moderate memory difficulty in 22
(44%) subjects. Over the course of the study, CSF pleocy-
tosis was no more common in subjects with or without
these symptoms. There were no significant time trends.
Similarly, CSF pleocytosis was not related to neuropsy-
chological test performance when results were considered
as a continuous variable or dichotomized as clinically
impaired (NPZ4 ≤ -0.5) vs. not impaired (NPZ4 > -0.5)
(data not shown). In this analysis, we controlled for
improved performance on the neuropsychological test
battery at sequential visits, which may reflect a practice
effect.
Discussion
HIV can cause mild CSF pleocytosis. Indeed, at the base-
line visit, 30% of our subjects had pleocytosis. We show
that across all visits, lack of use of antiretroviral agents,
CD4 count > 200/ul and detectable plasma viral load
independently and significantly increase the odds of CSF
pleocytosis, presumably due to HIV itself. Although CSF
viral load was associated with CSF pleocytosis in bivariate
analysis, the association was lost in multivariate analysis.
At visits where antiretrovirals were used, and taking into
account detectable plasma HIV RNA, an antiretroviral reg-
imen that contained two or more agents with good CNS
penetration conferred a trend toward lower odds of CSF
pleocytosis. The relationships that we observed between
CSF pleocytosis, antiretroviral use and CNS penetration of
a given regimen support the contention that CSF pleocy-
tosis is a direct reflection of CSF HIV infection.
The focus of our study differs from others because we
addressed factors that predict CSF pleocytosis rather than
the influence of CSF pleocytosis on CSF HIV replication.
Our results extend previous observations. Specifically, we
provide quantitative estimates of the odds of CSF pleocy-
tosis based on clinical features that are easy to identify:
antiretroviral use, CD4 count and plasma HIV RNA.
Because each of these three variables is significantly and
independently associated with CSF pleocytosis, multiply-
ing the odds ratios of these covariates for an individual
patient can provide an overall estimate of the odds of CSF
Table 1: Subject Characteristics at the Entry Visit
Characteristic Value
Age, years, median (range) 41.5 (23–64)
Male, n (%) 39 (78%)
Race, n (%) White, not Hispanic 33 (66%)
Black, not Hispanic 10 (20%)
Hispanic 4 (8%)
Other 3 (6%)
Years of education, median (range) 13 (9–18)
NPZ4, mean (standard deviation) -0.46 (0.72)
Current antiretroviral use, n (%) 33 (66%)
ARVs with good CNS penetration, median (range) 3 (0–4)
Two or more ARVs with good CNS penetration, n (%) 28 (85%)
Peripheral blood CD4+ T cells/ul, median (range) 467 (3–1016)
Plasma HIV RNA (49 subjects)
Detectable n (%) 29 (58%)
RNA log copies/ml in those with detectable plasma HIV RNA, median (range) 3.50 (1.82–5.48)
CSF WBC
WBC > 5/ul, n (%) 15 (30%)
CSF WBC in those with > 5/ul, median, (range) 13 (7–51)
CSF HIV RNA
Detectable, n (%) 17 (34%)
CSF HIV RNA log copies/ml in those with detectable CSF HIV RNA, median (range) 2.92 (1.71–4.08)
HIV, human immunodeficiency virus
NPZ4, normalized score on four neuropsychological tests
RNA, ribonucleic acid
CSF, cerebrospinal fluid
WBC, white blood cell
Detectable, > 50 copies/ml
ARV, antiretroviral agentPage 3 of 5
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direct clinical relevance to the situation of an HIV-infected
patient with suspected CSF or CNS infection and CSF ple-
ocyosis. When the overall odds of HIV-related CSF pleocy-
tosis are low, as they would be for an individual with
advanced HIV infection currently on antiretroviral ther-
apy with suppressed plasma viremia, an explanation for
CSF pleocytosis other than HIV should be sought.
In contrast to our results, a recent cross-sectional analysis
identified only a weak correlation between CSF WBCs and
CD4 count, and found no relationship between CSF pleo-
cytosis and plasma viral load [1]. In agreement with their
results, we found no relationship between cognitive com-
plaints or NPZ4 in subjects with or without CSF pleocyto-
sis. Differences between study results may be due to
several factors. Our subjects had less advanced HIV dis-
ease. Because CSF WBCs, our dependent variable, shows a
mixed distribution, it could not be modeled as a continu-
ous outcome. Thus we used the dichotomous component
of this variable because of its clear clinical relevance, and
we measured the contributions of peripheral viral load,
CD4 count and antiretroviral therapy to pleocytosis
jointly, rather than individually.
Limitations of our study should be noted. Our sample size
was modest, limiting power to detect some associations.
However, using GEE models allowed us to analyze data
from all 143 subject visits, and we identified several signif-
icant associations. Ours was a convenience sample, but
our subjects demographically and clinically resembled
our HIV clinic population, suggesting that our results may
be generalizable to HIV-infected patients in clinical care in
similar communities. Subjects did not have intercurrent
illnesses based on record review, history and clinical
examination. It is possible that we could have misclassi-
fied asymptomatic meningitis as due to HIV when it
might have been due to some other process. However,
such misclassification would likely have weakened, rather
than strengthened, our ability to identify associations
between CSF pleocytosis, peripheral blood CD4+ T cells,
plasma HIV RNA and use of potent antiretrovirals.
Conclusion
CSF pleocytosis is a characteristic of HIV disease that var-
ies significantly with easily identifiable clinical and labo-
ratory features. Knowledge of these factors is essential in
interpreting the CSF profile of such individuals when they
are evaluated for CNS infections other than HIV, such as
meningitis or encephalitis. Our data provide a practical
approach to address this issue.
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